Autopsy report · NCT04578548
A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Cause of deathFutility
“The study was early terminated due to lack of efficacy.”
Life of this trial
- Registered 1 month before it started.
- Ran for about 2 years 5 months before it stopped.
- 66 participants enrolled.
- Results were posted on the registry 1 year 5 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Lakefront Biotherapeutics NV
- Sponsor type
- Industry
- Conditions
- Autosomal Dominant Polycystic Kidney Disease
- Interventions
- GLPG2737; Placebo
- Participants
- 66
- Sites
- 20
- Countries
- Belgium, Czechia, Germany, Italy, Netherlands, Poland, Spain
Trials that died the same way
- Platform Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With aOX40 (GSK3174998) in Participants With RRMM
“The study was terminated due to lack of efficacy.” - Dasatinib in Polycythemia Vera
“This study was terminated due to lack of efficacy.” - Oral EPI-7386 in Patients with Castration-Resistant Prostate Cancer
“Study was terminated early due to a lack of improved efficacy.” - A Study Of The Safety And Efficacy Of AG-013,958 In Subjects With Subfoveal Choroidal Neovascularization Associated With Age-Related Macular Degeneration
“This study was terminated due to a lack of efficacy.” - A Study of LY3405105 in Participants With Advanced Cancer
“The study was terminated for lack of sufficient efficacy.”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.